Knowledge and application of sonographic scoring models for ovarian cancer management among gynecologists in Saudi Arabia: A cross-sectional study (#107934)

First submission

Guidance from your Editor

Please submit by 9 Feb 2025 for the benefit of the authors (and your token reward) .



Structure and Criteria

Please read the 'Structure and Criteria' page for guidance.



Custom checks

Make sure you include the custom checks shown below, in your review.



Raw data check

Review the raw data.



Image check

Check that figures and images have not been inappropriately manipulated.

If this article is published your review will be made public. You can choose whether to sign your review. If uploading a PDF please remove any identifiable information (if you want to remain anonymous).

Files

Download and review all files from the materials page.

- 1 Figure file(s)
- 5 Table file(s)
- 1 Raw data file(s)
- 1 Other file(s)

Q Custom checks

Human participant/human tissue checks

- Have you checked the authors ethical approval statement?
- Does the study meet our <u>article requirements</u>?
- Has identifiable info been removed from all files?
- Were the experiments necessary and ethical?

Structure and Criteria



Structure your review

The review form is divided into 5 sections. Please consider these when composing your review:

- 1. BASIC REPORTING
- 2. EXPERIMENTAL DESIGN
- 3. VALIDITY OF THE FINDINGS
- 4. General comments
- 5. Confidential notes to the editor
- You can also annotate this PDF and upload it as part of your review

When ready submit online.

Editorial Criteria

Use these criteria points to structure your review. The full detailed editorial criteria is on your guidance page.

BASIC REPORTING

- Clear, unambiguous, professional English language used throughout.
- Intro & background to show context.
 Literature well referenced & relevant.
- Structure conforms to <u>PeerJ standards</u>, discipline norm, or improved for clarity.
- Figures are relevant, high quality, well labelled & described.
- Raw data supplied (see <u>PeerJ policy</u>).

EXPERIMENTAL DESIGN

- Original primary research within Scope of the journal.
- Research question well defined, relevant & meaningful. It is stated how the research fills an identified knowledge gap.
- Rigorous investigation performed to a high technical & ethical standard.
- Methods described with sufficient detail & information to replicate.

VALIDITY OF THE FINDINGS

- Impact and novelty is not assessed.

 Meaningful replication encouraged where rationale & benefit to literature is clearly stated.
- All underlying data have been provided; they are robust, statistically sound, & controlled.



Conclusions are well stated, linked to original research question & limited to supporting results.

Standout reviewing tips



The best reviewers use these techniques

Τ	p

Support criticisms with evidence from the text or from other sources

Give specific suggestions on how to improve the manuscript

Comment on language and grammar issues

Organize by importance of the issues, and number your points

Please provide constructive criticism, and avoid personal opinions

Comment on strengths (as well as weaknesses) of the manuscript

Example

Smith et al (J of Methodology, 2005, V3, pp 123) have shown that the analysis you use in Lines 241-250 is not the most appropriate for this situation. Please explain why you used this method.

Your introduction needs more detail. I suggest that you improve the description at lines 57-86 to provide more justification for your study (specifically, you should expand upon the knowledge gap being filled).

The English language should be improved to ensure that an international audience can clearly understand your text. Some examples where the language could be improved include lines 23, 77, 121, 128 – the current phrasing makes comprehension difficult. I suggest you have a colleague who is proficient in English and familiar with the subject matter review your manuscript, or contact a professional editing service.

- 1. Your most important issue
- 2. The next most important item
- 3. ...
- 4. The least important points

I thank you for providing the raw data, however your supplemental files need more descriptive metadata identifiers to be useful to future readers. Although your results are compelling, the data analysis should be improved in the following ways: AA, BB, CC

I commend the authors for their extensive data set, compiled over many years of detailed fieldwork. In addition, the manuscript is clearly written in professional, unambiguous language. If there is a weakness, it is in the statistical analysis (as I have noted above) which should be improved upon before Acceptance.



Knowledge and application of sonographic scoring models for ovarian cancer management among gynecologists in Saudi Arabia: A cross-sectional study

Rana Aldahlawi Corresp. 1

1 Department of Radiology Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia

Corresponding Author: Rana Aldahlawi Email address: rdahlawi@ksu.edu.sa

Background. Ovarian cancer is a significant global health concern, ranking as the seventh most common cancer and the eighth leading cause of cancer-related deaths among women. Annually, it claims the lives of approximately 207,000 women worldwide. Early detection is crucial, as most cases are diagnosed at advanced stages, resulting in a five-year survival rate of less than 20%. Common diagnostic tools include Cancer Antigen 125 (CA125) and ultrasound, but these methods are limited by sensitivity, specificity, and operator dependence. The Risk of Malignancy Index (RMI) and the ADNEX model, which integrates ultrasound and CA125, offer improved diagnostic accuracy. This study aims to assess the knowledge and application of these models among gynecologists in Saudi Arabia.

Methods. A cross-sectional study was conducted involving 148 gynecologists from various hospitals in Saudi Arabia. Participants completed a structured questionnaire designed to evaluate their knowledge and application of the RMI and ADNEX models. Data was analyzed using descriptive statistics, and factors influencing the utilization of these models were identified through multivariate logistic regression analysis.

Results. The study found that 72% of the gynecologists were familiar with the RMI, and 58% were aware of the ADNEX model. However, only 46% reported regularly using the RMI, and 32% used the ADNEX model in their practice. Key barriers to the application of these models included a lack of training (56%), and limited access to necessary diagnostic tools (48%). Gynecologists with more than 10 years of experience were significantly more likely to use the RMI (OR: 2.5, 95% CI: 1.3 - 4.8) and the ADNEX model (OR: 2.1, 95% CI: 1.1 - 4.0).

Conclusion. This study reveals that gynecologists in Saudi Arabia are familiar with sonographic scoring models like RMI and ADNEX, although their application varies considerably. RMI is more commonly used. Since ADNEX provides more detailed analysis, expanded training is needed to increase its utilization. Specialists and experienced gynecologists demonstrate higher proficiency compared to general gynecologists and those with less experience, pointing to the need for targeted educational initiatives.



1 Knowledge and application of sonographic scoring

- 2 models for ovarian cancer management among
- gynecologists in Saudi Arabia: A cross-sectional
- 4 study

5

Rana Aldahlawi

7

- 8 Radiological Sciences Department, College of Applied Medical Sciences, King Saud University,
- 9 Riyadh, Saudi Arabia
- 10 Email address: rdahlawi@ksu.edu.sa

11

12

Abstract

- 13 **Background.** Ovarian cancer is a significant global health concern, ranking as the seventh most
- 14 common cancer and the eighth leading cause of cancer-related deaths among women. Annually,
- 15 it claims the lives of approximately 207,000 women worldwide. Early detection is crucial, as
- most cases are diagnosed at advanced stages, resulting in a five-year survival rate of less than
- 17 20%. Common diagnostic tools include Cancer Antigen 125 (CA125) and ultrasound, but these
- methods are limited by sensitivity, specificity, and operator dependence. The Risk of Malignancy
- 19 Index (RMI) and the ADNEX model, which integrates ultrasound and CA125, offer improved
- 20 diagnostic accuracy. This study aims to assess the knowledge and application of these models
- 21 among gynecologists in Saudi Arabia.
- 22 Methods. A cross-sectional study was conducted involving 148 gynecologists from various
- 23 hospitals in Saudi Arabia. Participants completed a structured questionnaire designed to evaluate
- 24 their knowledge and application of the RMI and ADNEX models. Data was analyzed using
- 25 descriptive statistics, and factors influencing the utilization of these models were identified
- 26 through multivariate logistic regression analysis.
- 27 **Results.** The study found that 72% of the gynecologists were familiar with the RMI, and 58%
- 28 were aware of the ADNEX model. However, only 46% reported regularly using the RMI, and
- 29 32% used the ADNEX model in their practice. Key barriers to the application of these models
- included a lack of training (56%), and limited access to necessary diagnostic tools (48%).
- 31 Gynecologists with more than 10 years of experience were significantly more likely to use the
- 32 RMI (OR: 2.5, 95% CI: 1.3 4.8) and the ADNEX model (OR: 2.1, 95% CI: 1.1 4.0).
- 33 Conclusion. This study reveals that gynecologists in Saudi Arabia are familiar with sonographic
- 34 scoring models like RMI and ADNEX, although their application varies considerably. RMI is
- 35 more commonly used. Since ADNEX provides more detailed analysis, expanded training is
- 36 needed to increase its utilization. Specialists and experienced gynecologists demonstrate higher
- 37 proficiency compared to general gynecologists and those with less experience, pointing to the
- 38 need for targeted educational initiatives.



Introduction

- 40 Ovarian cancer is a significant global health concern. It ranks as the seventh most common
- 41 cancer in women worldwide and is the eighth leading cause of cancer-related deaths among
- 42 women. According to the World Ovarian Cancer Coalition, approximately 207,000 women die
- 43 from this disease each year. Early detection is crucial for improving survival rates, as most cases
- are diagnosed at an advanced stage, with a five-year survival rate of less than 20% (Schoutrop et
- 45 al. 2022).
- 46 Cancer Antigen 125 (CA125) is a commonly used tumor marker for assessing ovarian cancer.
- 47 However, its effectiveness is limited due to its lack of sensitivity and specificity. CA125 levels
- are elevated in only 50% of patients with stage 1 ovarian cancer. Additionally, elevated CA125
- 49 levels can occur in numerous benign conditions such as endometriosis, adenomyosis, and pelvic
- 50 inflammatory disease, as well as in several non-gynecological conditions, including
- 51 diverticulitis, liver and heart failure, and cancers of the pancreas, breast, bladder, and liver
- 52 (Ronco et al. 2011).
- 53 Although ultrasound is excellent for detecting benign and malignant adnexal tumors, its
- 54 effectiveness is significantly influenced by the operator and equipment, making it somewhat
- subjective (Shung 2015). A general concern in gynecological ultrasound is the lack of
- standardized terms and procedures in image interpretation (Timmerman et al. 2011). Researchers
- 57 have combined ultrasound with CA125 measurements to improve the sensitivity and specificity
- of differentiating between benign and malignant masses, leading to the establishment of the Risk
- of Malignancy Index (RMI) (Jacobs et al. 1990). The RMI assigns one point to each of the
- 60 following gray-scale characteristics: ascites, intra-abdominal metastases, solid regions, bilateral
- lesions, and multilocular lesions. A score of U=0 represents 0 points, U=1 represents 1 point, and
- 62 U=3 represents 2 or more points. At a cut-off score of 200, the RMI has a specificity of 97% and
- a sensitivity of 85%. In 1996, Tingulstad updated the RMI to RMI II, which was recommended
- by the Royal College of Obstetricians and Gynecologists (Tingulstad et al. 1996). However, RMI
- 65 II has a sensitivity of 89% and a specificity of 73% (Liu et al. 2023).
- 66 The International Ovarian Tumor Analysis (IOTA) group developed the Assessment of Different
- 67 NEoplasias in the Adnexa (ADNEX) model. This model utilizes three clinical predictors (age,
- 68 serum CA125 level, type of center) and six ultrasound predictors (lesion diameter, solid tissue
- 69 proportion, cyst locules, papillary projections, acoustic shadows, and ascites) to preoperatively
- 70 differentiate between benign, borderline, stage 1 invasive, stage 2-4 invasive, and metastatic
- 71 ovarian tumors (Van Calster et al. 2014b). One of the advantages of the ADNEX model is its
- ability to calculate risk even without serum CA125 level information, although this results in a
- 73 decrease in performance. The ADNEX model has demonstrated excellent discrimination
- 74 between benign and malignant masses and has the potential to optimize the management of
- 75 women with adnexal masses. One large multicenter cohort study demonstrated the effectiveness
- of the ADNEX model in distinguishing between benign and malignant masses across all patients,
- 77 regardless of whether they were managed conservatively or surgically (Van Calster et al. 2020).
- 78 The study reported that the area under the receiver operating characteristic curve was highest for



- 79 ADNEX when combined with CA125 (0.94, 95% confidence interval 0.92 to 0.96), as well as
- 80 for ADNEX without CA125 (0.94, 0.91 to 0.95), and lowest for the RMI (0.89, 0.85 to 0.92).
- 81 Over the years, the model has been externally validated by numerous studies (Araujo et al. 2017;
- 82 Chen et al. 2022; Epstein et al. 2016; He et al. 2021; Sayasneh et al. 2016; Szubert et al. 2016;
- Viora et al. 2020), confirming its ability to discriminate between benign and malignant masses.
- 84 Moreover, the studies have shown that the proportion of solid tissue and serum CA125 level
- 85 were the strongest predictors, while the type of center was the weakest predictor, indicating that
- 86 other factors were more critical in determining the malignancy rate. A more recent study focused
- 87 on postmenopausal women concluded that using ADNEX as a risk prediction model can improve
- 88 the performance of pelvic ultrasound and effectively differentiate between benign and malignant
- 89 cysts, especially for undetermined lesions (Nohuz et al. 2019). Practitioners tasked with
- 90 managing ovarian masses preoperatively must be well-versed in widely accepted models, as they
- 91 facilitate precise differentiation between benign and malignant tumors, ultimately minimizing
- 92 unnecessary interventions and enhancing patient care.
- 93 Despite some gynecologists relying on subjective experience, proficient observers can
- 94 consistently distinguish lesions accurately. Nonetheless, acquiring and transferring this expertise
- 95 is challenging, highlighting the necessity of employing standardized models to ensure informed
- 96 decision-making and improve the management of ovarian masses (Valentin et al. 2011).
- 97 Therefore, applying morphology scoring systems such as the RMI or ADNEX model helps less
- 98 experienced operators make accurate judgments in gynecology and standardizes the protocol for
- 99 deciding on surgical intervention (Lee et al. 2005; Viora et al. 2020).

Materials & Methods

Study design and settings

100

- 103 This study employed a cross-sectional prospective quantitative observational design. It was
- 104 conducted at King Saud University in Riyadh, Saudi Arabia, with the survey distributed online.
- Data collection took place from December 2021 to December 2022. A questionnaire was
- disseminated electronically through emails and social media to the target population to ensure
- 107 quick response and was completed and submitted online.
- 108 The inclusion criteria for the study encompass all physicians employed in gynecology
- departments within Saudi Arabia, including specialists, gynecologists, and gyne-oncology
- 110 consultants. Exclusion criteria include sonographers, professionals from other medical
- 111 specialties, and physicians practicing outside of Saudi Arabia Professional statistical advice was
- sought to calculate the required sample size. A sample size of 148 responses was determined,
- based on a 1.96 standard deviation, 7.5% prevalence, and 0.035 precision.
- 114 Data collection tool
- 115 The questionnaire was written in a simple, brief format for ease of completion and consisted of
- three parts. The first part covers demographic characteristics such as gender, region of work,
- position (specialist, gynecology consultant, or gynecology consultant), years of experience, type
- of current hospital, and the number of patients seen weekly in the gynecology clinic. The second



- part assesses knowledge and experience using a 5-point Likert scale, querying training in
- 120 gynecology ultrasound scanning, availability of experienced sonographers, awareness of
- sonographic scoring models, the RMI, and the ADNEX model by the IOTA group, along with
- the need for national validation and updates with international guidelines. The third part explores
- 123 factors affecting surgical decision-making, considering various clinical features and diagnostic
- tools, the use of RMI and ADNEX models, and the influence of these scores on surgical
- decisions, as well as the use of other morphologic scoring systems for ovarian masses. Scores
- from seven Likert scale questions were aggregated for each respondent to calculate a total score
- ranging from 5 to 35. Two questions had scores ranging from 0 to 5, and the remaining five
- 128 questions ranged from 1 to 5. Participants were categorized based on percentile positions: scores
- below the 25th percentile were classified as "Poor," those between the 25th and 75th percentiles
- as "Moderate," and scores equal to or above the 75th percentile as "Good."
- 131 Ethical considerations
- 132 Ethical approval was obtained from the IRB committee at King Saud University Medical City
- 133 (KSUMC), approval number: E-21-6429. Completing the survey was considered as providing
- verbal consent by the respondents to participate in the study.
- 135 Statistical analysis
- 136 The statistical analysis in this study utilized SPSS version 26.0. Cronbach's Alpha was used to
- evaluate the validity and reliability of the knowledge and experience questionnaire. Qualitative
- variables were presented using frequencies and percentages, while continuous knowledge and
- experience scores were summarized using means and standard deviations. Fisher's exact tests
- 140 were conducted to explore associations between knowledge and experience categories, socio-
- 141 demographic variables, and the use of different sonographic scoring models. Significant
- variables from these tests were used to construct ordinal regression models, analyzing the
- relationship between the ordinal outcome variable and predictor variables. P-values less than
- 144 0.05 were considered statistically significant.

146 **Results**

- 147 **Table 1** presents the validity and reliability assessment of the questionnaire used to evaluate
- 148 knowledge and experience levels, comprising seven items with a Cronbach's Alpha coefficient of
- 149 0.631. Although Cronbach's Alpha falls below the recommended threshold of 0.65, indicating
- 150 lower reliability, the survey remains valid.
- 151 The study included 148 participants, with the highest representation from Riyadh (40.54%) and
- Makkah (33.11%) regions, followed by smaller cohorts from Tabouk, Qassim, Jawf, and Hail
- regions. Gender distribution showed a higher proportion of females (77.03%) compared to males
- 154 (22.97%). Among the participants, the majority were Gynecology consultants (60.81%), with a
- smaller percentage (6.76%) being gynecologic oncology consultants. Over half of the
- respondents (52.70%) had more than 15 years of experience in their respective fields.
- 157 Specialized hospitals were the predominant workplace (43.24%), followed by secondary
- hospitals (37.16%) and teaching and research hospitals (19.59%). Approximately one-third of the



159 clinicians reported seeing 10 to 20 patients weekly, while over half (53.38%) reported calculating the Risk of Malignancy Index (RMI) for their patients. Notably, a significant 160 proportion (40.54%) reported that the total score of RMI influenced their decision for surgical 161 intervention. Additionally, a smaller percentage (9.46%) reported using the ADNEX model, and 162 163 18.92% reported using other morphologic scoring systems. The mean knowledge scores indicated moderate levels of knowledge among participants, with scores ranging from 13.50 to 164 29.79 (Table 2). 165 Among the notable factors, the presence of specific ultrasound morphological features, such as 166 irregular walls, cysts, septation, solid areas, papillation, or echogenicity, was prevalent in 167 84.46% of cases. Similarly, the presence of ascites and the results of tumor markers, particularly 168 CA-125, were significant considerations, observed in 85.14% and 83.78% of cases, respectively. 169 The RMI and the ADNEX models were also influential, present in 75.68% and 40.54% of cases. 170 171 respectively. Other factors, including MRI and CT scans, patient wishes, and general medical 172 health, were also considered in making surgical decisions (**Table 3**). The majority of participants (66.89%) demonstrated a moderate level of knowledge and experience. A smaller fraction 173 (31.76%) demonstrated good knowledge and experience, while a minimal portion (1.35%) 174 showed poor proficiency (Figure 1). 175 Table 4 presents the analysis of knowledge and experience levels across various socio-176 demographic variables and the usage of sonographic scoring models among the study 177 respondents. The results indicate no significant differences in knowledge and experience levels 178 based on gender (p=0.722), work region (p=0.259), years of experience (p=0.345), and the 179 version of the RMI used (p=0.374). However, there were statistically significant differences in 180 181 knowledge and experience levels based on position (p=0.040), with gynecology oncology consultants having higher levels. The type of hospital also approached significance (p=0.053). 182 with specialized hospitals and teaching hospitals showing better knowledge and experience 183 levels. The calculation of RMI (p=0.003) and the use of the ADNEX model (p=0.019) were 184 185 significantly associated with higher knowledge and experience levels (Table 4). Table 5 displays the results of an ordinal regression analysis examining factors associated with 186 different levels of knowledge and experience. The transition from poor to moderate levels of 187 knowledge and experience was marked by a significant negative change (estimate: -3.534, 188 189 p<0.001). In contrast, shifting from moderate to good levels showed a significant positive change (estimate: 2.365, p<0.001). Regarding professional positions, gynecology consultants did not 190 significantly differ from specialists (p=0.237). Gynecology oncology consultants exhibited a 191 higher, though not statistically significant, level of knowledge and experience compared to 192 specialists (p=0.092). Consistent RMI calculation was significantly associated with higher levels 193

of knowledge and experience (estimate: 1.557, p=0.012). Similarly, both consistent (estimate: 1.684, p=0.009) and occasional (estimate: 1.531, p=0.002) use of the ADNEX model were

196 197

194

195

significantly associated with higher expertise levels.



Discussion

- 200 This study provides valuable insights into the knowledge and application of sonographic scoring
- 201 models among gynecologists in Saudi Arabia, specifically focusing on the RMI and the ADNEX
- 202 models. The findings highlight critical areas for improvement and emphasize the importance of
- these scoring models in clinical decision-making for ovarian masses.
- 204 Knowledge and application of sonographic scoring models
- 205 Our findings reveal that a significant proportion of gynecologists have moderate knowledge of
- 206 sonographic scoring models. This aligns with existing literature, which also indicates variability
- in the knowledge and application of these models among clinicians worldwide. For instance, Van
- Holsbeke et al. found that although the ADNEX model was effective in distinguishing between
- benign and malignant ovarian masses, its utilization varied significantly across different regions
- and healthcare settings (Van Holsbeke et al. 2009). This variability may be attributed to
- 211 differences in training, the availability of resources, and the complexity of cases encountered in
- 212 different clinical environments. Similarly, the use of the RMI has been widely adopted, yet its
- application is not universal, as highlighted by Meys et al., suggesting discrepancies in usage
- based on geographic and institutional factors (Meys et al. 2017).
- 215 The higher knowledge levels among gynecologic oncology consultants observed in our study are
- 216 consistent with findings from other research that emphasize the role of specialized training in
- 217 improving the use of diagnostic tools. Timmerman et al. demonstrated that gynecologic
- 218 oncologists are more likely to accurately interpret sonographic findings and apply scoring
- 219 models effectively due to their extensive training and experience in managing complex ovarian
- 220 masses (Timmerman et al. 2023). This highlights the need for continuous professional
- development and specialized training programs for general gynecologists to bridge the
- 222 knowledge gap. Research by Medeiros et al. further highlights that the effectiveness of the RMI
- 223 in improving diagnostic accuracy is significantly enhanced when users receive targeted training
- 224 (Medeiros et al. 2009).
- 225 A critical analysis of the literature reveals that while the ADNEX model provides a more
- 226 nuanced risk assessment by categorizing ovarian tumors into different histological subtypes, its
- 227 adoption is still limited compared to the RMI (Sayasneh et al. 2015). This may be due to the
- 228 more complex nature of the ADNEX model, which requires comprehensive ultrasound data and
- additional clinical information. In contrast, the RMI, which incorporates simpler parameters such
- as CA-125 levels, menopausal status, and ultrasound findings, is more straightforward to use and
- 231 interpret (Meys et al. 2017). This simplicity likely contributes to its wider acceptance and
- 232 application in various clinical settings. However, the reliance on CA-125 as a primary marker in
- 233 the RMI has its limitations, particularly in premenopausal women and in cases of borderline
- tumors where CA-125 levels may not be elevated. As noted by Jacobs et al., while CA-125 is a
- valuable marker, its specificity and sensitivity can be influenced by various benign conditions
- variable marker, its specificity and sensitivity can be influenced by various being conditions
- 236 (Jacobs et al. 1990).



239 Impact on clinical decision-making

- 240 The influence of the RMI and ADNEX models on clinical decisions regarding surgical
- 241 intervention is evident from our results, which are corroborated by previous studies. The RMI
- 242 and ADNEX models, by providing structured and evidence-based frameworks, significantly
- 243 enhance the accuracy of diagnosing ovarian masses and guide decisions regarding surgical
- 244 intervention. This is particularly critical in reducing unnecessary surgeries and improving patient
- outcomes. Geomini et al. reported that the use of the RMI significantly improved the accuracy of
- preoperative diagnosis, leading to better surgical planning and outcomes (Geomini et al. 2009).
- Despite its less frequent use, the ADNEX model's significant association with higher knowledge
- levels in our study suggests its potential utility in clinical practice. A study by Van Calster et al.
- 249 also highlighted that the use of the ADNEX model improves diagnostic accuracy, thereby
- 250 supporting more informed clinical decisions (Van Calster et al. 2014a). Kaijser et al. emphasized
- 251 the model's effectiveness in providing detailed risk assessments that guide surgical decisions,
- 252 particularly in differentiating between various types of ovarian tumors (Kaijser et al. 2013).
- 253 The study also identified key factors influencing surgical decisions, such as specific ultrasound
- 254 morphological features, the presence of ascites, and tumor marker results, particularly CA-125.
- 255 These factors are widely recognized in literature as critical determinants in the evaluation of
- ovarian masses. For instance, Timmerman et al. highlighted that specific ultrasound features,
- such as solid areas, multilocularity, and the presence of papillary projections, are strong
- 258 predictors of malignancy (Timmerman et al. 2000). Similarly, the presence of ascites is a well-
- 259 documented marker of advanced-stage ovarian cancer and is associated with poorer prognosis
- 260 (Jacobs et al. 1990).
- Moreover, the important role of CA-125, despite its limitations, has been reaffirmed in recent
- studies that suggest combining it with other biomarkers and imaging findings to improve
- 263 diagnostic performance. For example, Moore et al. demonstrated that the Risk of Ovarian
- 264 Malignancy Algorithm (ROMA), which combines CA-125 with HE4, provides superior
- 265 diagnostic accuracy compared to CA-125 alone (Moore et al. 2019). This integrated approach
- 266 can potentially reduce the rates of unnecessary surgeries and ensure timely intervention for
- 267 malignant cases.
- Our findings that a significant proportion of clinicians rely on RMI and, to a lesser extent, the
- 269 ADNEX model for surgical decision-making are consistent with these observations. Over half of
- 270 the respondents calculate the RMI, but a significantly lower percentage utilize the ADNEX
- 271 model, reflecting broader trends. This disparity can be attributed to several factors, including the
- 272 complexity of the models, as discussed earlier as well as the availability of necessary data, and
- 273 varying levels of training and confidence among practitioners. Recent advancements in training
- and the dissemination of standardized guidelines have aimed to address these gaps. For example,
- educational programs that emphasize hands-on training and the practical application of these
- 276 models have shown promise in enhancing clinician competence and confidence (Medeiros et al.
- 277 2009). Moreover, the integration of digital tools and online resources has facilitated access to
- 278 these scoring models, potentially increasing their usage. Despite these advancements, challenges

PeerJ

279 remain, particularly in ensuring that all clinicians, regardless of their location or institutional affiliation, have equal access to training and resources. This highlights the need for continued 280 efforts to standardize education and training on these models, as well as the importance of 281 ongoing research to identify and address barriers to their implementation. 282 283 Recent advancements in artificial intelligence (AI) and machine learning have shown the potential to enhance the predictive accuracy of these models, offering a promising avenue for 284 future research and development. For example, studies have demonstrated that AI algorithms can 285 analyze complex sonographic data more efficiently and accurately than traditional methods, 286 potentially augmenting the capabilities of existing scoring models (Kaijser et al. 2013). 287 Furthermore, debates in literature highlight the need for continuous evaluation and refinement of 288 these models. Some researchers argue for the inclusion of additional clinical variables and 289 biomarkers to improve predictive accuracy, while others emphasize the importance of validating 290 291 these models across diverse populations and clinical settings (Sayasneh et al. 2015). This 292 underscores the dynamic nature of this field and the necessity for ongoing research to refine and adapt these models to evolving clinical needs and technological advancements. 293 The nuanced application of sonographic scoring models holds substantial potential to enhance 294 patient management by accurately differentiating between individuals who are candidates for 295 conservative management and those necessitating prompt surgical intervention. For instance, the 296 ADNEX model's capability to classify ovarian tumors into distinct histological subtypes 297 significantly enhances the precision and personalization of surgical planning, which can improve 298 patient outcomes and reduce operative morbidity (Jacobs et al. 1990). 299 Exploring new directions 300 301 Addressing the moderate knowledge levels among gynecologists requires innovative educational interventions to improve understanding and application of sonographic scoring models. 302 Developing comprehensive training programs and workshops focused on the practical use and 303 interpretation of these models could address the knowledge gaps identified in this study. 304 305 Incorporating these models into standard clinical protocols and guidelines could promote consistent and evidence-based practice. To further enhance the impact and utilization of 306 sonographic scoring models, several future research pathways can be explored. First, barrier 307 identification and overcoming strategies should be a focus. Research should delve into the 308 309 barriers to the adoption of sonographic scoring models and identify strategies to overcome these challenges. Understanding the reasons behind the variability in model usage across different 310 regions and healthcare settings can inform targeted interventions. Second, investigating the long-311 term outcomes of patients managed using these models could provide valuable evidence to 312 support their routine use in clinical practice. Longitudinal studies can track patient progress and 313 314 outcomes, offering insights into the effectiveness of the models over time. Third, studies examining the effectiveness of educational interventions in improving knowledge and the 315 application of these models would also be beneficial. By assessing the impact of various training 316 programs, researchers can determine the most effective methods for enhancing clinician 317

competence in using sonographic scoring models. Lastly, the potential of emerging technologies,



319	such as artificial intelligence and machine learning, to enhance the predictive accuracy of
320	sonographic scoring models warrants exploration (Moore et al. 2019). Integrating these advanced
321	technologies can lead to the development of more sophisticated and reliable diagnostic tools.
322	Strengths and limitations
323	This study offers valuable insights into the knowledge and application of sonographic scoring
324	models among Saudi gynecologists, particularly focusing on the RMI and the ADNEX model.
325	The research employed a methodologically robust approach, combining structured questionnaires
326	and interviews to gather comprehensive data from a diverse sample of practitioners across
327	different regions. The analysis, blending qualitative and quantitative methods, provided a
328	nuanced understanding of factors influencing model adoption. Practical implications include
329	actionable recommendations for targeted training and integration into clinical guidelines,
330	potentially impacting healthcare practices positively.
331	Despite its strengths, the study has several limitations to consider. The sample size, while
332	diverse, may not fully represent all gynecologists practicing in Saudi Arabia, limiting the
333	generalizability of findings. Contextual factors such as variations in hospital settings and patient
334	demographics were not extensively explored, which could influence model adoption rates.
335	Additionally, the cross-sectional design restricts the ability to establish causal relationships over
336	time, suggesting a need for longitudinal studies to track evolving practice patterns and
337	intervention outcomes accurately.
338	
339	Conclusions
340	This study reveals that gynecologists in Saudi Arabia are familiar with sonographic scoring
341	models like RMI and ADNEX, although their application varies considerably. RMI is more
~ 4 ~	

This study reveals that gynecologists in Saudi Arabia are familiar with sonographic scoring models like RMI and ADNEX, although their application varies considerably. RMI is more commonly used. Since ADNEX provides more detailed analysis, expanded training is needed to increase its utilization. Specialists and experienced gynecologists demonstrate higher proficiency than general gynecologists and those with less experience, pointing to the need for targeted educational initiatives. Continuous medical education is vital for improving diagnostic accuracy and patient outcomes. Enhancing knowledge and application of these models will lead to more informed decisions and better management of ovarian masses, ultimately advancing gynecological practice in the region.

349 350

35**2** 35**3**

Acknowledgements

The author would like to express sincere gratitude to the gynecologists who participated in this study and provided invaluable insights into the diagnostic processes of ovarian masses.

355 356 357

358

359

References

Araujo KG, Jales RM, Pereira PN, Yoshida A, de Angelo Andrade L, Sarian LO, and Derchain S. 2017. Performance of the IOTA ADNEX model in preoperative discrimination of



369

377 378

379

380

389

390

391

392

393

- 360 adnexal masses in a gynecological oncology center. Ultrasound Obstet Gynecol 49:778-361 783. 10.1002/uog.15963
- Chen GY, Hsu TF, Chan IS, Liu CH, Chao WT, Shih YC, Jiang LY, Chang YH, Wang PH, and 362 363 Chen YJ. 2022. Comparison of the O-RADS and ADNEX models regarding malignancy rate and validity in evaluating adnexal lesions. Eur Radiol 32:7854-7864. 364 10.1007/s00330-022-08803-6 365
- Epstein E, Van Calster B, Timmerman D, and Nikman S. 2016. Subjective ultrasound 366 assessment, the ADNEX model and ultrasound-guided tru-cut biopsy to differentiate disseminated primary ovarian cancer from metastatic non-ovarian cancer. *Ultrasound* 368 Obstet Gynecol 47:110-116. 10.1002/uog.14892
- Geomini P, Kruitwagen R, Bremer GL, Cnossen J, and Mol BW. 2009. The accuracy of risk 370 371 scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 113:384-394. 10.1097/AOG.0b013e318195ad17 372
- 373 He P, Wang JJ, Duan W, Song C, Yang Y, and Wu QQ. 2021. Estimating the risk of malignancy of adnexal masses: validation of the ADNEX model in the hands of nonexpert 374 375 ultrasonographers in a gynaecological oncology centre in China. J Ovarian Res 14:169. 376 10.1186/s13048-021-00922-w
 - Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, and Grudzinskas JG. 1990. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 97:922-929. 10.1111/j.1471-0528.1990.tb02448.x
- Kaijser J, Bourne T, Valentin L, Sayasneh A, Van Holsbeke C, Vergote I, Testa AC, Franchi D, 381 382 Van Calster B, and Timmerman D. 2013. Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies. 383 *Ultrasound Obstet Gynecol* 41:9-20. 10.1002/uog.12323 384
- 385 Lee TS, Kim JW, Park NH, Song YS, Kang SB, and Lee HP. 2005. Assessing clinical performance of gynecology residents: sonographic evaluation of adnexal masses based on 386 morphological scoring systems. Ultrasound Obstet Gynecol 26:776-779. 387 388 10.1002/uog.2622
 - Liu YN, Tan X, Xiong W, Dong X, Liu J, Wang ZL, and Chen HX. 2023. Natural history and malignant potential of simple ovarian cysts in postmenopausal women: a systematic review and meta-analysis. *Menopause* 30:559-565. 10.1097/GME.000000000002163
 - Medeiros LR, Rosa DD, da Rosa MI, and Bozzetti MC. 2009. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol 142:99-105. 10.1016/j.ejogrb.2008.08.011
- Meys EMJ, Jeelof LS, Achten NMJ, Slangen BFM, Lambrechts S, Kruitwagen R, and Van Gorp 395 T. 2017. Estimating risk of malignancy in adnexal masses: external validation of the 396 397 ADNEX model and comparison with other frequently used ultrasound methods. 398 *Ultrasound Obstet Gynecol* 49:784-792. 10.1002/uog.17225
- Moore RG, Blackman A, Miller MC, Robison K, DiSilvestro PA, Eklund EE, Strongin R, and 399 400 Messerlian G. 2019. Multiple biomarker algorithms to predict epithelial ovarian cancer in 401 women with a pelvic mass: Can additional makers improve performance? Gynecologic oncology 154:150-155. 402
- Nohuz E, De Simone L, and Chene G. 2019. Reliability of IOTA score and ADNEX model in 403 404 the screening of ovarian malignancy in postmenopausal women. J Gynecol Obstet Hum 405 Reprod 48:103-107. 10.1016/j.jogoh.2018.04.012



434

435

- Ronco DA, Manahan KJ, and Geisler JP. 2011. Ovarian cancer risk assessment: a tool for 406 407 preoperative assessment. Eur J Obstet Gynecol Reprod Biol 158:325-329. 10.1016/j.ejogrb.2011.05.018 408
- 409 Sayasneh A, Ekechi C, Ferrara L, Kaijser J, Stalder C, Sur S, Timmerman D, and Bourne T. 2015. The characteristic ultrasound features of specific types of ovarian pathology 410 (review). Int J Oncol 46:445-458. 10.3892/ijo.2014.2764 411
- 412 Sayasneh A, Ferrara L, De Cock B, Saso S, Al-Memar M, Johnson S, Kaijser J, Carvalho J, 413 Husicka R, Smith A, Stalder C, Blanco MC, Ettore G, Van Calster B, Timmerman D, and 414 Bourne T. 2016. Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study. Br J Cancer 115:542-548. 415 416 10.1038/bjc.2016.227
- Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, and 417 Magalhaes I. 2022. Molecular, cellular and systemic aspects of epithelial ovarian cancer 418 419 and its tumor microenvironment. Semin Cancer Biol 86:207-223. 10.1016/j.semcancer.2022.03.027 420
- 421 Shung K. 2015. Diagnostic Ultrasound: Imaging and Blood Flow Measurements. Boca Raton: 422 CRC Press.
- 423 Szubert S, Wojtowicz A, Moszynski R, Zywica P, Dyczkowski K, Stachowiak A, Sajdak S, 424 Szpurek D, and Alcazar JL. 2016. External validation of the IOTA ADNEX model 425 performed by two independent gynecologic centers. Gynecol Oncol 142:490-495. 426 10.1016/j.ygyno.2016.06.020
- Timmerman D, Valentin L, Bourne T, Collins W, Verrelst H, and Vergote I. 2000. Terms, 427 428 definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. 429 Ultrasound in Obstetrics and Gynecology: The Official Journal of the International 430 431 Society of Ultrasound in Obstetrics and Gynecology 16:500-505.
 - Timmerman D, Van Calster B, Vergote I, Van Hoorde K, Van Gorp T, Valentin L, and Bourne T. 2011. Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol 118:1179-1181. 10.1097/AOG.0b013e31823584db
- 436 Timmerman S, Valentin L, Ceusters J, Testa AC, Landolfo C, Sladkevicius P, Van Holsbeke C, 437 Domali E, Fruscio R, Epstein E, Franchi D, Kudla MJ, Chiappa V, Alcazar JL, Leone 438 FPG, Buonomo F, Coccia ME, Guerriero S, Deo N, Jokubkiene L, Kaijser J, Scambia G, 439 Andreotti R, Timmerman D, Bourne T, Van Calster B, and Froyman W. 2023. External Validation of the Ovarian-Adnexal Reporting and Data System (O-RADS) Lexicon and 440 the International Ovarian Tumor Analysis 2-Step Strategy to Stratify Ovarian Tumors 441 Into O-RADS Risk Groups. JAMA Oncology 9:225-233. 10.1001/jamaoncol.2022.5969 442
- Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, and Nustad K. 1996. 443 444 Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 445 103:826-831. 10.1111/j.1471-0528.1996.tb09882.x 446
- 447 Valentin L, Ameye L, Savelli L, Fruscio R, Leone FP, Czekierdowski A, Lissoni AA, Fischerova D, Guerriero S, Van Holsbeke C, Van Huffel S, and Timmerman D. 2011. Adnexal 448 masses difficult to classify as benign or malignant using subjective assessment of gray-449 450 scale and Doppler ultrasound findings: logistic regression models do not help. *Ultrasound*

451 Obstet Gynecol 38:456-465. 10.1002/uog.9030

- Van Calster B, Valentin L, Froyman W, Landolfo C, Ceusters J, Testa AC, Wynants L,
 Sladkevicius P, Van Holsbeke C, Domali E, Fruscio R, Epstein E, Franchi D, Kudla MJ,
 Chiappa V, Alcazar JL, Leone FPG, Buonomo F, Coccia ME, Guerriero S, Deo N,
 Jokubkiene L, Savelli L, Fischerova D, Czekierdowski A, Kaijser J, Coosemans A,
 Scambia G, Vergote I, Bourne T, and Timmerman D. 2020. Validation of models to
 diagnose ovarian cancer in patients managed surgically or conservatively: multicentre
 cohort study. BMJ 370:m2614. 10.1136/bmj.m2614
- Van Calster B, Van Hoorde K, Valentin L, Testa AC, Fischerova D, Van Holsbeke C, Savelli L,
 Franchi D, Epstein E, Kaijser J, Van Belle V, Czekierdowski A, Guerriero S, Fruscio R,
 Lanzani C, Scala F, Bourne T, and Timmerman D. 2014a. Evaluating the risk of ovarian
 cancer before surgery using the ADNEX model to differentiate between benign,
 borderline, early and advanced stage invasive, and secondary metastatic tumours:
 prospective multicentre diagnostic study. *BMJ*: *British Medical Journal* 349:g5920.
 10.1136/bmj.g5920
- Van Calster B, Van Hoorde K, Valentin L, Testa AC, Fischerova D, Van Holsbeke C, Savelli L,
 Franchi D, Epstein E, Kaijser J, Van Belle V, Czekierdowski A, Guerriero S, Fruscio R,
 Lanzani C, Scala F, Bourne T, Timmerman D, and International Ovarian Tumour
 Analysis G. 2014b. Evaluating the risk of ovarian cancer before surgery using the
 ADNEX model to differentiate between benign, borderline, early and advanced stage
 invasive, and secondary metastatic tumours: prospective multicentre diagnostic study.
 BMJ 349:g5920. 10.1136/bmj.g5920
- Van Holsbeke C, Van Calster B, Testa AC, Domali E, Lu C, Van Huffel S, Valentin L, and
 Timmerman D. 2009. Prospective internal validation of mathematical models to predict
 malignancy in adnexal masses: results from the international ovarian tumor analysis
 study. *Clinical Cancer Research* 15:684-691.
- Viora E, Piovano E, Baima Poma C, Cotrino I, Castiglione A, Cavallero C, Sciarrone A,
 Bastonero S, Iskra L, and Zola P. 2020. The ADNEX model to triage adnexal masses: An
 external validation study and comparison with the IOTA two-step strategy and subjective
 assessment by an experienced ultrasound operator. *Eur J Obstet Gynecol Reprod Biol* 247:207-211. 10.1016/j.ejogrb.2020.02.022

Figure 1

Distribution of knowledge and experience levels of participants






Table 1(on next page)

Validity and reliability of the questionnaire



PeerJ

1

Knowledge and experience level assessing questions	No. of items	Cronbach's Alpha based on standardized items
	7	0.631



Table 2(on next page)

Demographic variables, some factors, and knowledge score of the study participants (n=148)

SD: Standard deviation; RMI: Risk of malignancy index; ADNEX: Assessment of Different NEoplasias in the adnexa



Variables	Scale	N (%), Mean \pm SD
Gender	Female	114 (77.03)
	Male	34 (22.97)
Region	Asir	3 (2.03)
	Eastern Region	13 (8.78)
	Hail	1 (0.68)
	Jawf	1 (0.68)
	Jazan	2 (1.35)
	Madinah	12 (8.11)
	Makkah	49 (33.11)
	Qassim	6 (4.05)
	Riyadh	60 (40.54)
	Tabouk	1 (0.68)
Position	Gynecology oncology consultant	10 (6.76)
	Gynecology consultant	90 (60.81)
	Specialist	48 (32.43)
Experience (years)	2-5 years	14 (9.46)
	6-10 years	23 (15.54)
	11-15 years	33 (22.30)
	More than 15 years	78 (52.70)
Type of hospital	Secondary hospital (150 beds or more)	55 (37.16)
	Specialized hospital (Tertiary)	64 (43.24)
	Teaching and Research Hospital	29 (19.59)
Number of patients seen	Less than 10	13 (8.78)
every week	10 to 20	49 (33.11)



	21 - 30	39 (26.35)
	31 - 40	47 (31.76)
Calculate the RMI	Yes	79 (53.38)
	Some of them	34 (22.97)
	No	35 (23.65)
The version of RMI used	RMI I	61 (41.22)
	RMI II	20 (13.51)
	Other version (RMI IV)	6 (4.05)
Total score of RMI affects	Yes	60 (40.54)
the decision for surgical intervention	Some of them	48 (32.43)
	No	16 (10.81)
	Not applicable	21 (14.19)
Calculate ADNEX model	Yes	14 (9.46)
	Some of them	31 (20.95)
	No	103 (69.59)
Use other morphologic	Yes	28 (18.92)
scoring systems	Sometimes	23 (15.54)
	Rarely	7 (4.73)
	No	90 (60.81)
Knowledge score	Poor	13.50 ± 0.71
	Moderate	24.12 ± 2.84
	Good	29.79 ± 1.83



Table 3(on next page)

Factors affecting the decision for surgical intervention

RMI: Risk of malignancy index; ADNEX: Assessment of Different Neoplasias in the adnexa;

MRI: Magnetic resonance imaging; CT: Computed tomography



Factors	N (%)
Overall ultrasound morphology of the ovary	88 (59.46)
Ovarian diameter and size	85 (57.43)
Specific features e.g. irregular walls, number of cysts, septation, solid areas, papillation or echogenicity	125 (84.46)
Presence of abnormal morphology bilateral	96 (64.86)
Presence of doppler signal in abnormal area	83 (56.08)
Presence of ascites	126 (85.14)
Results of tumor marker CA-125	124 (83.78)
Other tumor markers	86 (58.11)
RMI	112 (75.68)
ADNEX model	60 (40.54)
MRI	101 (68.24)
CT	72 (48.65)
Other considerations: general medical health and suitability for surgery	84 (56.76)
Patient wishes	74(50.00)



Table 4(on next page)

Analysis of knowledge and experience levels across socio-demographic variables and sonographic scoring model usage among the study participants (n=148)

RMI: Risk of malignancy index; ADNEX: Assessment of Different NEoplasias in the adnexa; *: Statistically significant



Variable	Category	Poor (%)	Moderate (%)	Good (%)	p- value
Gender	Female	2 (100.00)	74 (74.75)	38 (80.85)	0.722
	Male	0 (0.00)	25 (25.25)	9 (19.15)	
Work region	Asir	0 (0.00)	2 (2.02)	1 (2.13)	0.259
_	Eastern Region	0 (0.00)	6 (6.06)	7 (14.89)	
	Hail	0 (0.00)	0 (0.00)	1 (2.13)	
	Jawf	0 (0.00)	1 (1.01)	0 (0.00)	
	Jazan	0 (0.00)	0 (0.00)	2 (4.26)	
	Madinah	0 (0.00)	8 (8.08)	4 (8.51)	_
	Makkah	1 (50.00)	37 (37.37)	11 (23.40)	
	Qassim	0 (0.00)	5 (5.05)	1 (2.13)	_
	Riyadh	1 (50.00)	40 (40.40)	19 (40.43)	
	Tabouk	0 (0.00)	0 (0.00)	1 (2.13)	_
Position	Gynecology	0 (0.00)	3 (3.03)	7 (14.89)	0.040*
	oncology consultant				
	Gynecology Consultant	2 (100.00)	65 (65.66)	23 (48.94)	_
	Specialist	0 (0.00)	31 (31.31)	17 (36.17)	_
Experience (years)	11-15 years	0 (0.00)	22 (22.22)	11 (23.40)	0.345
	2-5 years	1 (50.00)	9 (9.09)	4 (8.51)	_
	6-10 years	0 (0.00)	19 (19.19)	4 (8.51)	
	> 15 years	1 (50.00)	49 (49.49)	28 (59.57)	_
Type of hospital	Secondary hospital (150 beds or more)	1 (50.00)	43 (43.43)	11 (23.40)	0.053
	Specialized hospital (tertiary)	0 (0.00)	39 (39.39)	25 (53.19)	_
	Teaching and Research Hospital	1 (50.00)	17 (17.17)	11 (23.40)	
Number of patients	less than 10	1 (50.00)	9 (9.09)	3 (6.38)	0.243
seen every week	10-20	0 (0.00)	37 (37.37)	12 (25.53)	_
	21-30	0 (0.00)	25 (25.25)	14 (29.79)	_
	31-40	1 (50.00)	28 (28.28)	18 (38.30)	_
Calculate the RMI	Yes	1 (50.00)	47 (47.47)	31 (65.96)	0.003*
	Some of them	0 (0.00)	21 (21.21)	13 (27.66)	
	No	1 (50.00)	31 (31.31)	3 (6.38)	
Version of RMI used	RMI I	0 (0.00)	39 (39.39)	22 (46.81)	0.374
	RMI II	0(0.00)	13 (13.13)	7 (14.89)	



	Other version (RMI IV)	1 (50.00)	4 (4.04)	1 (2.13)	
A total score of	Yes	0 (0.00)	38 (38.38)	22 (46.81)	0.350
RMI affects the	Some of them	1 (50.00)	30 (30.30)	17 (36.17)	
decision for	Not applicable	1 (50.00)	17 (17.17)	3 (6.38)	
surgical	No	0 (0.00)	10 (10.10)	6 (12.77)	
intervention					
Calculate ADNEX	Yes	0 (0.00)	5 (5.05)	9 (19.15)	0.019^{*}
model	Some of them	1 (50.00)	12 (12.12)	18 (38.30)	
	No	1 (50.00)	82 (82.83)	20 (42.55)	
Use other	Yes	0 (0.00)	18 (18.18)	10 (21.28)	0.417
morphologic	Sometimes	1 (50.00)	12 (12.12)	10 (21.28)	
scoring systems	Rarely	0 (0.00)	6 (6.06)	1 (2.13)	
	No	1 (50.00)	63 (63.64)	26 (55.32)	_



Table 5(on next page)

Ordinal regression analysis for knowledge and experience level and associated predictors

RMI: Risk of malignancy index; ADNEX: Assessment of Different NEoplasias in the adnexa; *: Statistically significant



			Estimate (95% Confidence Interval)	p-value
Knowledge and experience level = poor to moderate		-3.534 (-5.150 to 1.918)	<0.001*	
Knowledge and experience = moderate to good	ce level		2.365 (1.119 to 3.610)	<0.001*
Position	Gynecology consultant		-0.498 (-1.324 to 0.327)	0.237
	Gynecology consultant	oncology	1.461 (-0.238 to 3.160)	0.092
	Specialist		Reference	
Calculate the RMI for	Yes		1.557 (0.345 to 2.769)	0.012*
the patient	some of them		1.283 (-1.106 to 2.672)	0.07
	No		Reference	
Calculate the ADNEX	Yes		1.684 (0.414 to 2.954)	0.009*
model for the patient	some of them		1.531 (0.575 to 2.487)	0.002*
	No		Reference	